PI3K/Akt/mTOR Signaling
PI3K/Akt/mTOR signaling inhibitors are compounds that target the phosphoinositide 3-kinase (PI3K), Akt kinase, and mammalian target of rapamycin (mTOR) pathways. These pathways are critical regulators of cell growth, survival, metabolism, and autophagy, making them key targets in cancer research and metabolic disorders. Inhibiting these pathways can help to control tumor growth and proliferation, offering potential therapeutic strategies for various cancers and other diseases characterized by dysregulated cell signaling. At CymitQuimica, we offer a comprehensive selection of high-quality PI3K/Akt/mTOR inhibitors to support your research in oncology, cellular signaling, and metabolic diseases.
Subcategories of "PI3K/Akt/mTOR Signaling"
- AMPK(158 products)
- ATM/ATR(71 products)
- DNA-PK(51 products)
- EGFR(572 products)
- MELK(7 products)
- PDK(9 products)
- PI3K(242 products)
- S6 Kinase(9 products)
- gsk-3(112 products)
- mTOR(144 products)
Show 2 more subcategories
Found 1038 products of "PI3K/Akt/mTOR Signaling"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
DS06652923
<p>DS06652923 is an orally active inhibitor targeting EGFR triple mutations. It exhibits growth-inhibitory effects on Ba/F3EGFRdel19/T90M/C795S cells, with a GI50 value of 9.4 nM. Additionally, DS06652923 induces tumor regression in the Ba/F3 syngeneic transplantation model.</p>Color and Shape:Odour SolidDA-143
<p>DA-143 is a selective inhibitor of DNA-PKcs (IC50: 2.5 nM), demonstrating disparate inhibitory effects on mTOR, PI3KΔ, and ATM, with IC50 values of 280 nM, 106 nM, and 6,594 nM, respectively. This compound effectively blocks the phosphorylation of DNA-PKcs substrates and enhances the sensitivity of cancer cells to doxorubicin.</p>Color and Shape:Odour SolidPI3Kδ-IN-8
CAS:<p>PI3Kδ-IN-8 is a powerful and specific oral inhibitor of PI3Kδ, exhibiting an IC50 of 3.3 nM.</p>Formula:C28H21F2N7OColor and Shape:SolidMolecular weight:509.521mTOR inhibitor WYE-28
CAS:<p>Compound 28 (mTOR inhibitor WYE-28) is a selective inhibitor of mTOR (IC50=0.08 nM). Also inhibits PI3Kα (IC50 6 nM).</p>Formula:C30H34N8O5Color and Shape:SolidMolecular weight:586.653PI3Kα-IN-25
<p>PI3Kα-IN-25 (Compound Djh1) is a selective inhibitor of PI3Kα, suitable for research in triple-negative breast cancer.</p>Formula:C21H19ClN4O4Color and Shape:SolidMolecular weight:426.853HER2-IN-14
CAS:<p>HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.</p>Formula:C26H23ClF2N8O3Color and Shape:SolidMolecular weight:568.96EGFR-IN-124
<p>EGFR-IN-124 (compound 10A) is an EGFR inhibitor with an IC50 value of 0.54 μM, utilized in cancer research.</p>Color and Shape:Odour SolidEGFR-IN-127
<p>EGFR-IN-127 is an ATP-competitive inhibitor targeting EGFR, with IC50 values of 136.3 nM for EGFRdel19 and 161.2 nM for EGFRdel19/T790M/C797S. This compound holds potential for the study of non-small cell lung cancer (NSCLC).</p>Color and Shape:Odour SolidHL-8
CAS:<p>HL-8, a PROTAC targeting PI3K, degrades it fully at 10 μM in 8h, useful in cancer research.</p>Formula:C57H59F2N11O9S2Color and Shape:SolidMolecular weight:1144.27GSK-3β inhibitor 21
<p>GSK-3β Inhibitor21 (compound 44) is an ATP-competitive inhibitor of GSK-3β with an IC50 value of 6.06 µM, characterized by its ability to inhibit tau phosphorylation and prevent amyloid protein aggregation. This compound is utilized in the research of Alzheimer's disease.</p>Color and Shape:Odour SolidCetuximab MMAE
<p>Cetuximab-MMAE, an antibody-drug conjugate (ADC), combines an EGFR-targeting antibody with Monomethyl auristatin E (MMAE) to investigate colorectal and head and neck cancers.</p>Color and Shape:LiquidMolecular weight:150 kDaVarlitinib Tosylate
CAS:<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Formula:C36H35ClN6O8S3Purity:98%Color and Shape:SolidMolecular weight:811.34PI3K-IN-22
CAS:<p>PI3K-IN-22 is a dual kinase inhibitor of PI3Kα and mTOR, with IC50s of 0.9 and 0.6 nM respectively. PI3K-IN-22 could be used in cancer.</p>Formula:C31H35F3N8O3Color and Shape:SolidMolecular weight:624.66HER2/neu (654-662) GP2
CAS:<p>Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.</p>Formula:C42H77N9O11Purity:98%Color and Shape:SolidMolecular weight:884.11EGFR/PI3Kα-IN-1
<p>EGFR/PI3Kα-IN-1 (compound 30k), a dual EGFR/PI3Kα inhibitor, exhibits potent activity with IC 50 values of 3.6 nM (EGFRL858R/T790M) and 30 nM (PI3Kα). It effectively inhibits tumor cell proliferation and demonstrates significant anticancer activity.</p>Formula:C50H49N11O5SColor and Shape:SolidMolecular weight:916.06RMC-4529
CAS:<p>RMC-4529 is a chemical compound that demonstrates potent inhibition, with an IC50 value of 1.0 nM, against p-4E-BP1-(T37/46) in mTOR kinase cellular assays.</p>Formula:C90H139N13O23Color and Shape:SolidMolecular weight:1771.17Tephrosin
CAS:<p>Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors, has potent antitumor activities.</p>Formula:C23H22O7Purity:98%Color and Shape:SolidMolecular weight:410.42Amdizalisib
CAS:<p>Amdizalisib is a PI3K inhibitor and used for the research of inflammatory disease, autoimmune disease or cancer.</p>Formula:C19H15ClN8Color and Shape:SolidMolecular weight:390.84IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Color and Shape:Odour LiquidUmbralisib R-enantiomer
CAS:<p>Umbralisib R-enantiomer (RP5264 R-enantiomer) is a delta inhibitor of PI3K and a less active enantiomer of TGR-1202.</p>Formula:C31H24F3N5O3Purity:97.34%Color and Shape:SolidMolecular weight:571.55
